Intrinsiqq
Filana Therapeutics, Inc. logo

Filana Therapeutics, Inc. Insider Trading

FLNA

Compare
Cluster buy

4 insiders bought 368K of their own stock in 3 days.

Open-market purchases by executives and directors between Nov 16 and Nov 18. Buying is rarer than selling and says more, but it is one input, not a verdict.

Net open-market
+749K
9 buys · 0 sales
Under a 10b5-1 plan
—
no sales
Insiders who bought / sold
4 / 0
executives and directors
Last open-market buy
Nov 2026
Nov 18, 2026

Get an email when FLNA's executives or directors buy, or make a large sale outside a plan.

Trades · last 2 years

  • Nov 18
    Robert Eugene Anderson Jr
    Director · bought 19,000 at $0.52
    10K
    221% of stake
  • Nov 18
    Richard Barry
    President & CEO · bought 44,851 at $0.52
    23K
    2.3% of stake
  • Nov 17
    Richard Barry
    President & CEO · bought 132,926 at $0.48
    64K
    7.5% of stake
  • Nov 16
    Richard Barry
    President & CEO · bought 440,206 at $0.47
    207K
    33% of stake
  • Nov 16
    Eric Schoen
    Chief Financial Officer · bought 20,000 at $0.42
    8K
    174% of stake
  • Nov 16
    Robert Christopher Cook
    Chief Operating& Legal Officer · bought 121,575 at $0.46
    56K
    886% of stake
  • Sep 29 – 30
    Richard Barry
    President & CEO · bought 306,813 at avg $0.91
    278K
    30% of stake
  • Sep 28
    Richard Barry
    President & CEO · bought 93,091 at $0.84
    78K
    9.9% of stake
  • Nov 24, 2025
    Robert Eugene Anderson Jr
    Director · bought 8,600 at $2.90
    25K
    New position
  • Nov 20, 2025
    Richard Barry
    President & CEO · bought 150,000 at $2.76
    414K
    19% of stake
  • Nov 19, 2025
    Richard Barry
    President & CEO · bought 73,385 at $2.75
    202K
    10% of stake
  • Sep 30, 2025
    Robert Christopher Cook
    Chief Operating & Legal Office · bought 13,725 at $2.91
    40K
    New position
  • Sep 22, 2025
    Richard Barry
    President & CEO · bought 7,172 at $2.28
    16K
    1.0% of stake
  • Sep 18, 2025 – Sep 19, 2025
    Richard Barry
    President & CEO · bought 237,941 at avg $2.25
    535K
    51% of stake
  • Nov 29, 2024No plan
    James William Kupiec
    Chief Medical Officer · sold 4,000 at $3.87
    15K
    100% of stake
  • Nov 29, 2024No plan
    Eric Schoen
    Chief Financial Officer · sold 61,800 at avg $3.86
    238K
    84% of stake
How to read this. Insiders sell for many reasons: taxes, diversifying, a house. Open-market buys are rarer and say more. A 10b5-1 plan is a trading schedule set up months in advance, so those sales were not timed on news. Large holders (funds and 10% owners) are listed under Everything but not counted as insiders. If you own or watch FLNA, we send a push when an executive buys or makes a large sale outside a plan.

Source: SEC Form 4 filings, filed within two business days of each trade and checked for new ones every hour.

Peers

Pharmaceutical Preparations · Pick stocks to compare with FLNA

CompareIntrinsic value
EQEquillium, Inc.
$1.06-5.36%40
ROIVRoivant Sciences Ltd
$38.66-0.78%42
NERVMinerva Neurosciences Inc.
$2.00-5.66%10
KROSKeros Therapeutics Inc.
$11.08-2.72%20
CRNXCrinetics Pharmaceuticals Inc.
No recent price40
ENVBEnveric Biosciences Inc.
$1.35-4.26%21
PVLAPavella Therapeutics Inc.
$143.21-1.76%40
TNXPTonix Pharmaceuticals Holding Corp
$2.38-6.67%40

Held by ETFs

FLNA is in 2 US ETFs. The largest of them, with FLNA's weight in each:

Spot a number that looks wrong? Check it in FLNA's SEC filings or

Download this analysis as a PDF (Pro)

Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.

5 of 5 free stocks used today

Keep analysing FLNA

A free account gives you 10 stocks a day, a watchlist and price alerts.

Already have an account?

Or come back tomorrow. Stocks on your watchlist are always free to view.

MarketsPrivacyTerms© 2026 Intrinsiqq

Not financial advice. Analytical data for research only.

Intrinsiqq is a Netherlands-based company operating in Rotterdam, KvK 73238007.